Detail akcie IONBEAM APPL online

Business Summary: Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Ion Beam Applications SA revenues increased 24% to EUR620.2M. Net income applicable to common stockholders increased 37% to EUR12.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from equity method decrease of 56% to EUR900K (expense). Dividend per share increased from EUR0.17 to EUR0.18.